Melanoma, Malignant, of Soft Parts Clinical Trial
— COWBOYOfficial title:
Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY
Rationale:
The combination of ipilimumab and nivolumab induces relatively high response rates and
promising response depth in late stage melanoma. Nevertheless, it takes time till responses
occur and still a significant number of patients do not benefit from treatment, due to rapid
progressive disease or resistance to therapy.
In contrast to immunotherapies targeted therapies (BRAF or MEK inhibitors), can induce faster
and higher response rates, but often of shorter duration, even when combined.
Initial attempts of combining vemurafenib or dabrafenib + trametinib with ipilimumab failed
due to toxicity.
Patients with elevated levels of serum LDH are less likely to respond to immunotherapy
compared to patients with normal LDH levels. This does not mean that such patients do not
benefit at all from immunotherapy.
This raises the question, whether response rates upon immunotherapy can be improved by
upfront reduction of tumor burden and normalization of LDH.
The investigators postulate that induction therapy with combined BRAF+MEK inhibition, and
subsequent LDH normalization, can improve response rates to the rates seen in LDH normal
patients.
To address this question the investigators have setup a randomized phase 2 trial in
metastatic melanoma patients with elevated serum LDH comparing the response rates upon
ipilimumab + nivolumab versus ipilimumab + nivolumab preceded by 6 weeks of vemurafenib +
cobimetinib induction.
Furthermore, less than half of the patients treated with the combination of ipilimumab and
nivolumab received maintenance nivolumab, and approximately 40% of all patients discontinued
treatment for toxicity. In 70% of patients responses were ongoing despite discontinuation of
treatment due to toxicity. This raises the question, to what extent does maintenance therapy
add clinical benefit to an ongoing immune response. Preclinical data indicate even that
continuous restimulation of T cells can result in activation induced non-responsiveness
(anergy).
Therefore, a secondary objective of this trial will be, to test a response-driven nivolumab
scheme
Objectives:
Primary Objective • To compare efficacy of induction vemurafenib + cobimetinib followed by
ipilimumab + nivolumab (Arm A) versus upfront ipilimumab + nivolumab treatment (Arm B).
Secondary Objectives
- To describe duration of response and overall survival induced by vemurafenib +
cobimetinib followed by the combination of ipilimumab + nivolumab (Arm A) as compared to
ipilimumab + nivolumab (Arm B)
- To describe the rate and quality of toxicity observed in the two study arms
- To describe the rate of ongoing responses upon response-driven flat dose (240mg q2w or
480mg q4w) nivolumab maintenance
- To determine the immune-activating capacity of induction therapy with vemurafenib +
cobimetinib followed by the combination of ipilimumab + nivolumab.
- To evaluate the changes in systemic immune competence
Study design:
This is a two-arm phase 2 study consisting of 200 BRAFV600E/K mutation-positive late-stage
melanoma patients with an elevated baseline LDH level (> ULN, < 3xULN) randomized 1:1
(stratified according to LDH) to receive either vemurafenib + cobimetinib directly followed
by ipilimumab + nivolumab (Arm A) or standard first line ipilimumab + nivolumab (Arm B).
Subsequently, patients in both arms will receive flat dose (240mg q2w or 480mg q4w) nivolumab
maintenance in a response-driven manner.
Study population:
Stage IV, or unresectable stage III, BRAFV600E/K mutation positive melanoma patients, naïve
for BRAF/MEK, PD-1/PD-L1 or CTLA-4 targeting therapy, 18 years and older.
Intervention:
Patients will be randomized 1:1 to receive either 6 weeks vemurafenib 960 mg bid +
cobimetinib 60 mg QD 21-day on, 7-day off (21/7) schedule, directly followed by 4 courses of
ipilimumab 3mg/kg q3wk + nivolumab 1mg/kg q3wk (Arm A) or first line standard 4 courses of
ipilimumab 3mg/kg q3wk + nivolumab 1mg/kg q3wk (Arm B).
Subsequently, patients in both arms will receive nivolumab maintenance flat dose (240mg q2w
or 480mg q4w) in a response-driven manner according to their response at week 18.
Main study parameters/endpoints:
Primary Endpoints
• Compare the best overall response rate (BORR) according to RECIST 1.1 of both arms at week
18 from start of treatment.
Secondary Endpoints
- Progression-free survival (PFS) according to RECIST 1.1
- Overall survival (OS)
- Percentage of grade 3/4 toxicities according to CTCv4.03
- Percentage of ongoing response, percentage of patients requiring re-induction, response
percentage upon re-induction
- Changes in tumor-specific T cell responses
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | October 2023 |
| Est. primary completion date | October 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Adults 18 years and older - World Health Organization (WHO) Performance Status 0-2 - Histologically or cytologically confirmed Stage IV, or unresectable stage III, BRAF V600E/K mutated melanoma - Measurable disease according to RECIST 1.1 - Signed and dated informed consent form - No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1 - No prior BRAFi and/ or MEKi therapy - No immunosuppressive medications - Screening laboratory values must meet the following criteria and should be obtained within 10 days prior to randomization: - WBC = 2.0x109/L, Neutrophils = 1.0x109/L, Platelets = 100 x109/L, Hemoglobin = 5.0 mmol/L - Creatinine = 2x ULN or creatinine clearance (CrCl) = 40 ml/min - AST, ALT = 3.0 x ULN (=5 x ULN for patients with liver metastases) - Bilirubin = 2.0 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL ) - LDH > ULN, < 5.0 x ULN - No symptomatic brain metastases (asysmptomatic brain metastases, accidentally found during screening can be included) - No leptomeningeal metastases - No active autoimmune disease requiring systemic treatment in the past 3 months or a documented history of autoimmune disease, or history of syndrome that required systemic steroids, at daily dose of =10mg prednisone or equivalent, or immunosuppressive medications. (Subjects with vitiligo or resolved childhood asthma/atopy are excluded from this rule (and will not be excluded from this study). Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.) - No evidence of interstitial lung disease or active, non-infectious pneumonitis - No active infection requiring therapy - No known additional malignancy that is progressing or requires active treatment - Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days + the time required for nivolumab to undergo five half-lives) after the last dose of study medication - WOBCP must have a negative serum or urine pregnancy test within 96 hours prior to the start of study treatment and must not be breast feeding - Men must agree to the use of male contraception during the study treatment period and for at least 31 weeks after the last dose of study drug. - Currently not participating in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment. - No underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events |
| Country | Name | City | State |
|---|---|---|---|
| Netherlands | The Netherlands Cancer Institute | Amsterdam | |
| Netherlands | Vrije Universiteit Medisch Centrum | Amsterdam | |
| Netherlands | Amphia Ziekenhuis Breda | Breda | |
| Netherlands | Maxima MC | Eindhoven | |
| Netherlands | Medisch Spectrum Twente | Enschede | |
| Netherlands | Universitair Medisch Centrum Groningen | Groningen | |
| Netherlands | Zuyderland Medisch Centrum Heerlen | Heerlen | |
| Netherlands | Leids Universitair Medisch Centrum | Leiden | |
| Netherlands | Maastricht UMC+ | Maastricht | |
| Netherlands | Radboudumc | Nijmegen | |
| Netherlands | Erasmus MC | Rotterdam | |
| Netherlands | UMC Utrecht | Utrecht | |
| Netherlands | Isala | Zwolle |
| Lead Sponsor | Collaborator |
|---|---|
| Radboud University | Isala, The Netherlands Cancer Institute |
Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Best overall response rate (BORR) according to RECIST 1.1 | Week 18 from start of treatment | ||
| Secondary | Progression-free survival (PFS) according to RECIST 1.1 | 1 and 2 years from start of treatment | ||
| Secondary | Overall survival (OS) | 1 and 2 years from start of treatment | ||
| Secondary | Grade 3/4 toxicities according to CTCv4.03 | Week 18 from start of treatment | ||
| Secondary | Percentage of ongoing response | 1 and 2 years from start of treatment | ||
| Secondary | Response percentage upon re-induction | Week 18 from start of treatment | ||
| Secondary | Changes in tumor-specific T cell responses | Week 18 from start of treatment |